ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) on behalf of long-term stockholders following a class action complaint that was filed against Acadia on April 19, 2021 with a Class Period from June 15, 2020 to April 4, 2021. Our investigation concerns whether the board of directors of Acadia have breached their fiduciary duties to the company. Aca.

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

BioMarin Pharmaceutical

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Steve Davis - Chief Executive Officer Brendan Teehan - Chief Operating Officer, Head of Commercial Doug Williamson - Head of Research & Development Mark Schneyer - Chief Financial Officer Kathie Bishop - Chief Scientific Officer and Head of Rare Diseases Conference Call Participants Ritu Baral - TD Cowen Charles Duncan - Cantor Fitzgerald Tessa Romero - J.P. Morgan Tazeen Ahmad - Bank of America Neena Bitritto-Garg - Citi Rudy Li - SVB Securities Gregory Renza - RBC Capital Markets Jason Butler - JMP Jeff Hung - Morgan Stanley Yatin Suneja - Guggenheim Operator Good day, ladies and gentlemen.

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2023 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.70 per share a year ago.

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2023. “We are excited with the recent approval and subsequent launch of DAYBUE, the first and only FDA-approved medicine for the treatment of Rett syndrome. We are executing on our launch strategy to bring this important new treatment to the Rett patient community, while remaining focused on delivering increasing profitability from our NUPLAZID franc.

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 24, 2023, the Compensation Committee of Acadia's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 98,850 shares of common stock and 59,934 restricted stock units (“RSUs”) to 44 new employees under Acadia's 2023 Inducement Plan. The Compensation Committee of Acadia's Board of Directors approved the awards as an inducement material to the new emplo.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences: BofA Securities 2023 Health Care Conference Fireside Chat: Wednesday, May 10, 2023 at 2:20 p.m. Eastern Time in Las Vegas, NV The JMP Securities Life Sciences Conference Fireside Chat: Tuesday, May 16, 2023 at 2:30 p.m. Eastern Time in New York, NY 2023 RBC Capital Markets Global Healthcare Conference Fireside Chat: Wednesday, May 17, 20.

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

Shares of Acadia Pharmaceuticals Inc. have been stuck in a range for the last two years. The approval and launch of Daybue come at the right time - when Nuplazid is not growing anymore.

Acadia Pharmaceuticals: Better Times Ahead

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Monday, May 8, 2023, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on May 8, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call will be available on Acadia's website, www.acadia.com under the investors section and will be archived there unt.

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

Sanofi

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that four posters in Rett syndrome will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, being held April 22 – 27, 2023 in Boston, Mass. The poster presentations include a secondary analysis reporting on the communication-related endpoints from the pivotal Phase 3 LAVENDER™ study and an interim analysis of the ongoing, open-label DAFFODIL™ study.

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States. DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett syndrome. DAYBUE was approved by the U.S.

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 22nd Annual Needham Virtual Healthcare conference on Tuesday, April 18, 2023 at 1:30 p.m. Eastern Time. The conference will be held virtually. A live webcast of the presentation will be accessible on the company's website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.

Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio

ATLANTA--(BUSINESS WIRE)---- $ACAD #ALZN002--Alzamend Neuro Announces Initiation of Phase I/IIA Trial for Its Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Dementia of Alzheimer's Type

Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

ATLANTA--(BUSINESS WIRE)---- $ACAD #ALZN002--Alzamend Neuro Announces Initiation of Phase I/IIA Trial for Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

ATLANTA--(BUSINESS WIRE)---- $ACAD #ADDF--Alzamend Neuro Completes Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's

Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?

Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, according to a company spokesperson. The Food and Drug Administration on Friday approved Daybue, the first therapy to treat Rett syndrome, a rare disease that has been diagnosed in 4,500 adults and children in the U.S. The company said it expects to have the drug available in the U.S. by the end of April.

Acadia's rare-disease drug to cost $575,000 to $595,000

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.

Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome

Axsome Therapeutics

Roku

Market volatility seems to be the central theme for stocks heading into next week. These three Nasdaq-listed stocks may be among the most volatile.

3 Nasdaq Stocks on Watch This Week

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome. "Today marks an important milestone for the Rett community and Acadia.

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

Acadia Pharmaceuticals expects to learn the regulatory fate of its Rett syndrome candidate on March 12. This rare disease drug could drive the stock up by 21% or higher in the coming days.

News for ACADIA Pharma Stock (ACAD)